Rhumbline Advisers Day One Biopharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 85,438 shares of DAWN stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85,438
Previous 89,727
4.78%
Holding current value
$1.21 Million
Previous $1.48 Million
20.58%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding DAWN
# of Institutions
167Shares Held
71.7MCall Options Held
163KPut Options Held
183K-
Ra Capital Management, L.P. Boston, MA7.87MShares$111 Million1.63% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$90.9 Million11.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.62MShares$65.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$64.1 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.78MShares$53.4 Million0.02% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $1.04B
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...